Isthmus Partners, LLC Bristol Myers Squibb CO Transaction History

Isthmus Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$40.25 - $52.99 $65,084 - $85,684	1,617 New	1,617 $67,000
Q3 2021 Nov 10, 2021	SELL	$59.17 - $69.31 $178,515 - $209,108	-3,017 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$61.91 - $67.42 $186,782 - $203,406	3,017 New	3,017 $202,000
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $4.05 Million - $5.88 Million	-87,193 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $4.29 Million - $5.6 Million	87,193 New	87,193 $5.6 Million
Q2 2019 Aug 09, 2019	SELL	$44.62 - $49.34 $3.48 Million - $3.85 Million	-78,030 Closed	0 $0
Q1 2019 Apr 19, 2019	BUY	$45.12 - $53.8 $3.52 Million - $4.2 Million	78,030 New	78,030 $6.79 Million
Q4 2018 Feb 04, 2019	SELL	$48.76 - $63.23 $156,275 - $202,652	-3,205 Closed	0 $0
Q2 2018 Aug 02, 2018	SELL	$50.53 - $62.98 $15,159 - $18,894	-300 Reduced 8.56%	3,205 $177,000
Q3 2017 Nov 02, 2017	BUY	$55.23 - $63.74 $193,581 - $223,408	3,505	3,505 $223,000

2,535

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Isthmus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Isthmus Partners, LLC with notifications on news.